Share This Page
Drug Price Trends for NDC 16714-0795
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0795
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TERBINAFINE HCL 250 MG TABLET | 16714-0795-01 | 0.15128 | EACH | 2025-11-19 |
| TERBINAFINE HCL 250 MG TABLET | 16714-0795-02 | 0.15128 | EACH | 2025-11-19 |
| TERBINAFINE HCL 250 MG TABLET | 16714-0795-01 | 0.15007 | EACH | 2025-10-22 |
| TERBINAFINE HCL 250 MG TABLET | 16714-0795-02 | 0.15007 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0795
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0795
Introduction
This analysis provides a comprehensive overview of the market landscape and pricing outlook for the drug identified by NDC 16714-0795. This assessment considers current market dynamics, competitive positioning, regulatory environment, and pricing trends specific to the drug's therapeutic category. The objective is to equip pharmaceutical stakeholders, investors, and healthcare providers with actionable insights to inform decision-making processes.
Product Overview
NDC 16714-0795 corresponds to [Insert Drug Name], a [insert therapeutic class, e.g., monoclonal antibody, small molecule, biologic] indicated for [specify condition/indication, e.g., rheumatoid arthritis, oncology, rare diseases]. The drug has garnered attention owing to its [unique mechanism, clinical efficacy, safety profile, or novel therapeutic approach]. It is primarily marketed in the U.S. and possibly in select international markets, authorized via [FDA approval pathway, e.g., BLA, NDA].
Market Landscape
Market Size and Demand Drivers
The therapeutic area associated with NDC 16714-0795 exhibits a robust growth trajectory driven by:
- Increasing prevalence of the target condition: Rising incidence of [condition] has expanded the eligible patient population. For instance, [provide recent epidemiological data, e.g., the prevalence of the condition in the U.S. or globally].
- Medical advancements and treatment paradigm shifts: The drug's adoption is propelled by [novel mechanism, improved efficacy, enhanced safety profiles, or convenience] over existing therapies.
- Regulatory approvals and reimbursement policies: Favorable reimbursement status and expanded indications enhance market penetration prospects.
Competitive Positioning
Within its therapeutic class, NDC 16714-0795 faces competition from:
- Brand-name biologics or small molecules: Such as [competitors’ drugs] with established market shares.
- Emerging biosimilars or generics: Increasingly, biosimilars are entering the market, pressuring prices.
- Pipeline candidates: New entrants undergoing clinical development may threaten future market share.
The drug’s competitive advantages include [clinical efficacy, dosing convenience, safety profile, pharmacokinetics]. However, pricing strategies must account for biosimilar encroachment and payer negotiations.
Pricing Environment
Current Pricing Trends
As of [latest year], the average wholesale price (AWP) for [similar drugs or comparators] ranges from $[value] to $[value] per [dose, treatment course].
For NDC 16714-0795, initial list pricing has historically been in the $[range] bracket, consistent with:
- Biologic or specialty drug pricing norms.
- The drug’s novelty and therapeutic value.
- Pricing pressures from payers seeking cost containment.
In the private insurance segment, negotiated net prices tend to be [10-30%] lower than the list price, depending on payer contracts and patient assistance programs.
Pricing Trends and Forecast
A projection for [2023-2028] indicates:
- Moderate price erosion (~5-10% annually) due to biosimilar competition.
- Potential premium pricing possible during initial launch phases, especially if the drug demonstrates significant clinical benefits or orphan drug status, which can justify higher margins.
- Impact of policy changes: Proposed Medicare Price Negotiation policies and value-based frameworks are poised to influence peak prices.
Regulatory and Reimbursement Outlook
The drug’s regulatory status impacts pricing strategies:
- FDA approval has facilitated initial high pricing associated with novel biologics.
- Reimbursement policies are critical; favorable coverage pathways support sustained and maximized pricing levels.
- Market access hurdles stem from payer negotiations, prior authorization requirements, and the presence of biosimilar competitors.
Market Entry and Growth Projections
Initial Launch Phase (Years 1-2)
Market penetration is estimated at [percentage] of the eligible patient population, driven by:
- High unmet need or orphan drug exclusivity.
- Strong marketing and physician engagement.
Pricing is likely to be set at a premium to capitalize on market novelty, with initial average prices of $[value] per treatment course.
Mid to Long-Term Outlook (Years 3-5)
Expected price adjustment due to:
- Biosimilar competition, leading to a [10-20%] decline in list prices.
- Market saturation and expanded indication approvals.
By [year], projections suggest a stabilized average net price of $[value], with potential to maintain similar or slightly adjusted pricing depending on market acceptance and competitive landscape.
Implications for Stakeholders
- Pharmaceutical Companies: Strategic pricing during launch can optimize revenue, but must balance reimbursement realism with market competitiveness.
- Healthcare Providers: Adoption will be influenced by access, reimbursement policies, and clinical value.
- Payers: Cost containment pressures necessitate negotiations to contain expenditure while ensuring patient access.
- Investors: Long-term profitability hinges on market share expansion and managing biosimilar entry.
Key Challenges and Opportunities
- Pricing pressures due to biosimilar proliferation.
- Orphan drug designation may provide market exclusivity benefits, enabling premium pricing.
- Patient affordability and access are critical, especially as payers clamp down on high-cost biologics.
- Innovation and superior efficacy signatures can justify premium prices and extend market life.
Conclusion
NDC 16714-0795’s market prospects are promising given its therapeutic niche and current demand trends. However, the evolving pricing landscape, characterized by biosimilar competition and policy shifts, requires adaptable and strategic pricing approaches. Stakeholders should closely monitor regulatory developments, payer strategies, and market dynamics to optimize product value and ensure sustainable profitability.
Key Takeaways
- The drug targets a growing and underserved patient population, underpinned by recent clinical successes.
- Initial pricing is expected to be premium, reflecting therapeutic innovation, but will face downward pressure from biosimilars and policies.
- Long-term price stability will depend on market penetration, indication expansion, and competitive actions.
- Market strategies should incorporate early engagement with payers and health authorities to safeguard pricing power.
- Continuous market monitoring and pricing flexibility are vital to capitalize on emerging opportunities and mitigate risks.
FAQs
Q1: How does biosimilar competition affect the pricing of NDC 16714-0795?
A1: Biosimilars typically lead to significant price erosion, often 20% or more compared to the originator, as they offer lower-cost alternatives, forcing the original biologic to adjust pricing strategies accordingly.
Q2: What factors justify premium pricing during the initial launch?
A2: Factors include orphan drug designation, superior efficacy or safety profiles, convenience of administration, and lack of current effective therapies in the market.
Q3: How do regulatory policies influence pricing projections?
A3: Policies such as Medicare price negotiation, value-based pricing, and importation laws can cap or incentivize price adjustments, impacting long-term revenue potential.
Q4: What is the impact of market expansion on future prices?
A4: Approval for additional indications enlarges the patient base, potentially allowing for maintained or increased prices due to broader use, provided reimbursement pathways remain favorable.
Q5: How should companies prepare for potential pricing changes?
A5: Companies should develop flexible pricing strategies, engage early with payers, foster clinical differentiation, and explore value-based agreements to adapt to evolving market conditions.
Sources
[1] Medicare Payment Advisory Commission (MedPAC) reports on biologic drug pricing.
[2] IQVIA Biotech Reports on biologic market trends.
[3] FDA Drug Approvals and Labeling information.
[4] Industry analyst forecasts on biosimilar market penetration.
[5]Recent peer-reviewed publications on biologic pricing and reimbursement dynamics.
More… ↓
